Hirohisa Taniguchi
Overview
Explore the profile of Hirohisa Taniguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hatano K, Takata T, Takechi M, Wada A, Taniguchi H, Tamura Y
Heliyon
. 2025 Mar;
11(4):e42662.
PMID: 40028568
Introduction: The QT interval, a critical parameter in electrocardiography (ECG), is challenging to analyze accurately because of variations in T-wave morphology, especially in long-term ECG recordings, such as Holter monitoring....
2.
Tamura Y, Tamura Y, Takemura R, Yamada K, Taniguchi H, Iwasawa J, et al.
JACC CardioOncol
. 2023 Jan;
4(5):673-685.
PMID: 36636435
Background: Immune checkpoint inhibitors (ICIs) are a central part of cancer therapy; however, cardiac complications, such as myocarditis, have the potential for significant morbidity and mortality. Within this population, the...
3.
Yamada K, Tamura Y, Taniguchi H, Furukawa A, Iwasawa J, Yada H, et al.
Circ Rep
. 2022 Nov;
4(11):526-532.
PMID: 36408358
Trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is a specific first-line treatment for patients with HER2-positive cancers. Cardiac dysfunction is among the most problematic adverse events...
4.
Tamura Y, Tamura Y, Taniguchi H, Imanaka-Yoshida K
Circ J
. 2022 Oct;
87(2):376.
PMID: 36310041
No abstract available.
5.
Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, et al.
J Cardiol
. 2022 Aug;
81(1):63-67.
PMID: 35953399
Background: Immune checkpoint inhibitors (ICIs) improve clinical outcomes in various cancers, but sometimes induce autoimmune adverse effects, including myocarditis, which is the most serious complication. There are many reports on...
6.
Tamura Y, Tamura Y, Yamada K, Taniguchi H, Iwasawa J, Yada H, et al.
Heart Vessels
. 2022 May;
37(11):1859-1865.
PMID: 35633369
The indications for immune checkpoint inhibitors (ICIs) are expanding in cancer drug therapy, and while cardiac events associated with ICIs are often fatal, there are few reports regarding cardiac complications...
7.
Tamura Y, Furukawa A, Tamura Y, Yamada K, Taniguchi H, Fukuda K, et al.
Pulm Circ
. 2022 May;
12(1):e12058.
PMID: 35506073
There was no structured method for safely transition from parenteral prostanoids to oral medication. We enrolled 37 idiopathic/hereditary pulmonary arterial hypertension patients receiving triple combination therapy including parenteral prostanoids into...
8.
Furukawa A, Tamura Y, Yamada K, Taniguchi H, Ohashi N, Okabe T, et al.
Heart Vessels
. 2021 Oct;
37(4):601-608.
PMID: 34618189
Liver dysfunction is an important determinant of the prognosis of left heart failure patients. However, few studies have reported on cardiohepatic interactions in right heart failure patients, a condition that...
9.
Takashima T, Brisset S, Furukawa A, Taniguchi H, Takeyasu R, Kawamura A, et al.
Front Cardiovasc Med
. 2021 Sep;
8:711694.
PMID: 34589526
Mutations in the bone morphogenetic protein receptor type 2 gene () represent a major genetic cause of pulmonary arterial hypertension (PAH). Identification of mutations is crucial for the genetic diagnosis...
10.
Taniguchi H, Takashima T, Tu L, Thuillet R, Furukawa A, Furukawa Y, et al.
Pulm Circ
. 2021 Jul;
11(3):20458940211029550.
PMID: 34285798
Although precapillary pulmonary hypertension is a rare but severe complication of patients with neurofibromatosis type 1 (NF1), its association with NF2 remains unknown. Herein, we report a case of a...